CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers
S. S. K. Teh, K. Bowland, A. Bennett, E. Halper-Stromberg, A. Skaist, J. Tang, F. Cai, A. Macoretta, H. Liang, H. Kamiyama, S. Wheelan, M.-T. Lin, R. H. Hruban, R. B. Scharpf, N. J. Roberts, J. R. Eshleman
This paper demonstrates CRISPR-Cas9 can selectively target somatic mutations in pancreatic cancer by exploiting PAMs in noncoding regions, achieving >80% cell death with minimal off-target effects.
bioRxiv · Apr 15, 2023Cancer Biology